Gacyclidine intratympanic controlled-release - Otonomy

Drug Profile

Gacyclidine intratympanic controlled-release - Otonomy

Alternative Names: OTO 311; OTO 313

Latest Information Update: 12 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otonomy
  • Class Cyclohexanes; Neuroprotectants; Piperidines; Small molecules; Thiophenes
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Tinnitus

Most Recent Events

  • 16 Feb 2018 Otonomy plans a phase I/II trial for Tinnitus, in the first half of 2019 (Otonomy pipeline, February 2018)
  • 02 Mar 2017 Otonomy plans a phase II trial for tinnitus in the second half of 2017
  • 09 May 2016 Interim adverse events data from a phase I trial in Healthy volunteers released by Otonomy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top